New combo therapy shows promise for tough lung cancers
NCT ID NCT03527108
First seen Jan 20, 2026 · Last updated Jun 02, 2026 · Updated 16 times
Summary
This study tested a combination of two drugs, nivolumab and ramucirumab, in 36 adults with advanced non-small cell lung cancer that had come back or spread. All participants had already received immunotherapy. The main goal was to see if the combination could control the disease by shrinking tumors or stopping them from growing. This is not a cure, but aims to manage the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
NYU Langone
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.